APA

Scherl E. J., Pruitt R., Gordon G. L., Lamet M., Shaw A., Huang S., Mareya S. & Forbes W. P. (20090623). Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. : The American journal of gastroenterology.

Chicago

Scherl Ellen J, Pruitt Ronald, Gordon Glenn L, Lamet Mark, Shaw Audrey, Huang Shirley, Mareya Shadreck and Forbes William P. 20090623. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. : The American journal of gastroenterology.

Harvard

Scherl E. J., Pruitt R., Gordon G. L., Lamet M., Shaw A., Huang S., Mareya S. and Forbes W. P. (20090623). Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. : The American journal of gastroenterology.

MLA

Scherl Ellen J, Pruitt Ronald, Gordon Glenn L, Lamet Mark, Shaw Audrey, Huang Shirley, Mareya Shadreck and Forbes William P. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. : The American journal of gastroenterology. 20090623.